Global Gene Therapy for Age-related Macular Degeneration Market Growth (Status and Outlook) 2023-2029

Global Gene Therapy for Age-related Macular Degeneration Market Growth (Status and Outlook) 2023-2029

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

LPI (LP Information)' newest research report, the “Gene Therapy for Age-related Macular Degeneration Industry Forecast” looks at past sales and reviews total world Gene Therapy for Age-related Macular Degeneration sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy for Age-related Macular Degeneration sales for 2023 through 2029. With Gene Therapy for Age-related Macular Degeneration sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy for Age-related Macular Degeneration industry.

This Insight Report provides a comprehensive analysis of the global Gene Therapy for Age-related Macular Degeneration landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy for Age-related Macular Degeneration portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy for Age-related Macular Degeneration market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy for Age-related Macular Degeneration and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy for Age-related Macular Degeneration.

The global Gene Therapy for Age-related Macular Degeneration market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.

This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy for Age-related Macular Degeneration market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Subretinal
Intravitreal

Segmentation by application
Monotherapy
Combination Therapy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
RetroSense Therapeutics
REGENXBIO
AGTC

Please note: The report will take approximately 2 business days to prepare and deliver.